137 related articles for article (PubMed ID: 38316134)
1. Decitabine plus cedazuridine and venetoclax: the promise of an all-oral therapy for patients with myelodysplastic syndromes and chronic myelomonocytic leukaemia.
Assouline S
Lancet Haematol; 2024 Mar; 11(3):e170-e171. PubMed ID: 38316134
[No Abstract] [Full Text] [Related]
2. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study.
Bataller A; Montalban-Bravo G; Bazinet A; Alvarado Y; Chien K; Venugopal S; Ishizawa J; Hammond D; Swaminathan M; Sasaki K; Issa GC; Short NJ; Masarova L; Daver NG; Kadia TM; Colla S; Qiao W; Huang X; Kanagal-Shamanna R; Hendrickson S; Ravandi F; Jabbour E; Kantarjian H; Garcia-Manero G
Lancet Haematol; 2024 Mar; 11(3):e186-e195. PubMed ID: 38316133
[TBL] [Abstract][Full Text] [Related]
3. Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
Garcia-Manero G; McCloskey J; Griffiths EA; Yee KWL; Zeidan AM; Al-Kali A; Deeg HJ; Patel PA; Sabloff M; Keating MM; Zhu N; Gabrail NY; Fazal S; Maly J; Odenike O; Kantarjian H; DeZern AE; O'Connell CL; Roboz GJ; Busque L; Buckstein R; Amin H; Randhawa J; Leber B; Shastri A; Dao KH; Oganesian A; Hao Y; Keer HN; Azab M; Savona MR
Lancet Haematol; 2024 Jan; 11(1):e15-e26. PubMed ID: 38135371
[TBL] [Abstract][Full Text] [Related]
4. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study.
Bazinet A; Garcia-Manero G; Short N; Alvarado Y; Bataller A; Abuasab T; Islam R; Montalbano K; Issa G; Maiti A; Yilmaz M; Jain N; Masarova L; Kornblau S; Jabbour E; Montalban-Bravo G; Rausch CR; Pierce S; DiNardo CD; Kadia T; Daver N; Konopleva M; Huang X; Kantarjian H; Ravandi F
Lancet Haematol; 2024 Apr; 11(4):e276-e286. PubMed ID: 38452788
[TBL] [Abstract][Full Text] [Related]
5. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.
Savona MR; Odenike O; Amrein PC; Steensma DP; DeZern AE; Michaelis LC; Faderl S; Harb W; Kantarjian H; Lowder J; Oganesian A; Azab M; Garcia-Manero G
Lancet Haematol; 2019 Apr; 6(4):e194-e203. PubMed ID: 30926081
[TBL] [Abstract][Full Text] [Related]
6. Decitabine/Cedazuridine: First Approval.
Dhillon S
Drugs; 2020 Sep; 80(13):1373-1378. PubMed ID: 32860582
[TBL] [Abstract][Full Text] [Related]
7. Role of cedazuridine/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia.
Thota S; Oganesian A; Azab M; Griffiths EA
Future Oncol; 2021 Jun; 17(16):2077-2087. PubMed ID: 33709786
[TBL] [Abstract][Full Text] [Related]
8. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.
Bazinet A; Darbaniyan F; Jabbour E; Montalban-Bravo G; Ohanian M; Chien K; Kadia T; Takahashi K; Masarova L; Short N; Alvarado Y; Yilmaz M; Ravandi F; Andreeff M; Kanagal-Shamanna R; Ganan-Gomez I; Colla S; Qiao W; Huang X; McCue D; Mirabella B; Kantarjian H; Garcia-Manero G
Lancet Haematol; 2022 Oct; 9(10):e756-e765. PubMed ID: 36063832
[TBL] [Abstract][Full Text] [Related]
9. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.
Garcia-Manero G; Griffiths EA; Steensma DP; Roboz GJ; Wells R; McCloskey J; Odenike O; DeZern AE; Yee K; Busque L; O'Connell C; Michaelis LC; Brandwein J; Kantarjian H; Oganesian A; Azab M; Savona MR
Blood; 2020 Aug; 136(6):674-683. PubMed ID: 32285126
[TBL] [Abstract][Full Text] [Related]
10. New landscapes in the management of myelodysplastic syndromes and chronic myelomonocytic leukemia: oral decitabine.
Niscola P; Mazzone C; Molica M; de Fabritiis P
Future Oncol; 2021 Jun; 17(16):1973-1975. PubMed ID: 33878941
[No Abstract] [Full Text] [Related]
11. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia.
Montalban-Bravo G; Hammond D; DiNardo CD; Konopleva M; Borthakur G; Short NJ; Ramos-Perez J; Guerra V; Kanagal-Shamanna R; Naqvi K; Sasaki K; Jabbour E; Pemmaraju N; Kadia TM; Ravandi F; Daver N; Estrov Z; Pierce S; Kantarjian H; Garcia-Manero G
Leukemia; 2021 May; 35(5):1494-1499. PubMed ID: 33846541
[No Abstract] [Full Text] [Related]
12. Venetoclax/decitabine for a pediatric patient with chronic myelomonocytic leukemia.
Molina JC; Asare JM; Tuschong L; West RR; Calvo KR; Persky R; Boyce AM; Hammoud DA; Holland SM; Hickstein D; Shah NN
Pediatr Blood Cancer; 2021 Mar; 68(3):e28865. PubMed ID: 33369023
[TBL] [Abstract][Full Text] [Related]
13. Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies.
Patel AA; Cahill K; Saygin C; Odenike O
Blood Adv; 2021 Apr; 5(8):2264-2271. PubMed ID: 33904891
[TBL] [Abstract][Full Text] [Related]
14. Novel agents for myelodysplastic syndromes.
Xu K; Hansen E
J Oncol Pharm Pract; 2021 Dec; 27(8):1982-1992. PubMed ID: 34558354
[TBL] [Abstract][Full Text] [Related]
15. Fully oral regimen with decitabine and cedazuridine plus venetoclax: a new step forward for older or unfit patients with acute myeloid leukaemia.
Candoni A
Lancet Haematol; 2024 Apr; 11(4):e245-e246. PubMed ID: 38452789
[No Abstract] [Full Text] [Related]
16. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
17. Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience.
Azizi A; Ediriwickrema A; Dutta R; Patel SA; Shomali W; Medeiros B; Iberri D; Gotlib J; Mannis G; Greenberg P; Majeti R; Zhang T
Leuk Lymphoma; 2020 Nov; 61(11):2700-2707. PubMed ID: 32543932
[TBL] [Abstract][Full Text] [Related]
18. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M
Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931
[TBL] [Abstract][Full Text] [Related]
19. Decitabine and Cedazuridine.
Am J Health Syst Pharm; 2020 Oct; 77(22):1809-1811. PubMed ID: 32945859
[No Abstract] [Full Text] [Related]
20. Clinical update on hypomethylating agents.
Duchmann M; Itzykson R
Int J Hematol; 2019 Aug; 110(2):161-169. PubMed ID: 31020568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
